Measurements of plasma apolipoprotein A-I and B concentrations are increasingly used for the laboratory assessment of risk of coronary artery disease (CAD). This study of 22 patients investigated the response of plasma apolipoprotein A-I and B levels for up to 20 days following a myocardial infarction. Seven of these patients participated in a clinical trial using the drug Tissue Plasminogen Activator (TPA). We established that, unlike many other plasma proteins, apolipoproteins do not display a classic acute phase response following myocardial infarction, although large variations in plasma apolipoprotein levels were observed in the patients investigated. Our studies also show that the measurement of plasma apolipoproteins A-I and B to assess future CAD risk in myocardial infarction patients should be deferred for a minimum of at least 14 days post-infarction. No significant difference was observed in the pattern of apolipoprotein response between patients receiving TPA and those not given this drug.
Additional key phrases: coronary artery disease; acute phase response
The predictive value of the measurement of plasma apolipoproteins A-I and B in assessing the risk of coronary artery disease (CAD) has been widely established. Avogaro et al:' found in a large study that patients who had survived a myocardial infarction had significantly higher concentrations of apolipoprotein B (Apo B) and lower concentrations of apolipoprotein A-I (Apo A-I) than control subjects. Similar findings have been reported by other workers.?"
Franzen et al? stated that a low Apo A-I level alone was a better predictor of coronary artery disease in a five year retrospective study of patients who had survived an infarction. This finding has been supported by others"? Some groups have used the ratio of Apo A-I and B concentrations (or its inverse) as an index of cardiovascular disease risk. Noma et al. s and De Bacher et al. 9 have reported that use of the ratio improved discrimination between patients with and without coronary artery disease, throughout all age groups, when compared to individual apolipoprotein determinations.
It is also important to assess the risk of further coronary artery disease for patients who have just suffered a myocardial infarction. Many plasma proteins alter markedly in concentration in the period following a traumatic event such as Correspondence: Dr G H White. a myocardial infarction. Ifapolipoproteins are to be estimated during hospitalization to assess future CAD risk, it is important to determine whether they also show an acute phase response. In this study, we have measured apolipoproteins A-I and B for up to 20 days following myocardial infarction. C-reactive protein (CRP) was used as a marker of the acute phase response.
MATERIALS AND METHODS
Apolipoprotein A-I method An in-house immunoturbidimetric method was developed for the measurement of apolipoprotein A-I, based on a technique described by Austin and Maznicki," Rifai et al," and Mount et al" This method utilised the following reagents:
Apo A-l antiserum (anti-human-apolipoprotein A-I antiserum, Boehringer-Mannheim, FRG, catalogue number 726478). This was used undiluted as a start reagent.
Sample diluent (phosphate buffered saline pH 7,4). 1·74 g dipotassium hydrogen phosphate and 9 g sodium chloride were dissolved in one litre of water, and the pH adjusted to 7·4. Patients' samples were diluted I in 21 with sample diluent prior to analysis. Dilutions were stable for 7 days at 4°C. Analyses were performed on the Cobas Bio Centrifugal Analyser (Roche Analytical Instruments, Nutley, New Jersey, USA), using the instrument's DENS function which allows unknown concentrations to be calculated from a non-linear curve. Instrument settings are shown in Table I . Inter-assay coefficient of variation (CV) for this assay on the Cobas Bio was 1·9% at 1·25 giL Apo A-I.
Apolipoprotein B method
An in-house method for Apo B was also developed on the Cobas Bio. Apo B antibody (anti-human-apolipoprotein B antiserum, Boehringer-Mannheim, FRG, catalogue number 726494) was used undiluted as a start reagent. Sample diluent and apolipoprotein reagent were prepared as described for Apo A-I. Patient samples were diluted I in 21 with sample diluent prior to analysis and dilutions were shown to be stable for 7 days at 4°C. Cobas Bio settings used for the Apo B method are listed in Table I . Inter-assay CV was 2·4% at 0·78 giL Apo B.
Standards for apolipoprotein assays Using a .material standardised by the International Union of Immunological Science (CDC-lUIS Apolipoprotein RM Pool Number 1883, Clinical Chemistry Division, Centre for Disease Control, Atlanta, Georgia, USA), a set of working standards was prepared for use with the apolipoprotein methods. The CDC-lUIS standard, which had been assigned a value of 1·124 gl L for Apo A-I and 0·589 giL for Apo B in an international multicentre trial," was serially diluted with sample diluent to give standards with final concentrations of O· 39, O· 58, 0,87, 1,31, 1·97 and 2'95g/L for Apo A-I and 0,20, 0,31, 0·46, 0·69, 1·03 and 1·55 giL for Apo B.
C-reactive protein
A kit method (SPQ Test System for C-Reactive Protein, Atlantic Antibodies, Scarborough, Maine, USA, catalogue number 133-17) was used for this analyte. The kit contained the following reagents: antibody to C-reactive protein (60 mL goat antiserum), polymer diluent (lOOmL phosphate buffered saline containing 4% polyethylene glycol), a quality control material and a set of five standards. Standards, controls and patients' plasma were diluted I in 5 with polymer diluent, mixed and incubated for 15min, and centrifuged for 5 min at 4000 rpm. The supernatant was then analysed on the Cobas Bio according to the manufacturer's instructions (Table I) . Inter-assay CV was 6·3% at 48mg/L C-reactive protein.
Creatine kinase
Plasma creatine kinase (CK) levels were measured using a Roche kit method (Roche CK-NAC Ma-kit 10, catalogue number 0714542) on the Cobas Bio (Table I) . Inter-assay CV was 3-4% at 490 U/L.
Patient groups
Twenty-two patients (18 men, age range 42-89 years, and 4 women, age range 56-74 years), admitted to the Coronary Care Unit (CCU) at Flinders Medical Centre following myocardial infarction, 'were studied. Diagnosis of myocardial infarction was based on clinical history and typical electrocardiogram (ECG) and plasma enzyme activity changes.
Seven of the male patients (age range 43-69 years) participated in a clinical trial assessing the efficacy of the drug Tissue Plasminogen Activator (TPA). TPA converts plasminogen to plasmin, which can lyse thrombi in coronary arteries, thereby establishing earlier re-perfusion of cardiac tissue and decreasing the extent of myocardial damage.
Sample collection
All 22 patients underwent a standardised protocol of blood collection. Ten millilitres of venous blood (collected into lithium heparin, 15 Ujrnl), for the analysis of plasma apolipoproteins, CRP and CK levels, was taken from each patient on admission, and at 12, 24, 48, 72 and 120 h after admission. Samples were also collected at I, 2 and 3 weeks following admission from those patients who had survived their infarction and remained in hospital.
Plasma was separated and stored at 4°C within 2 h of blood collection, and all analyses were performed within 24 h of collection.
RESULTS AND DISCUSSION
Acute phase protein response Plasma concentrations of the acute phase protein CRP typically increased post-infarction and reached peak levels (often greater than 20 times the upper limit of the reference interval) approximately 24 h after the CK peak. The rise and subsequent fall in CRP levels was a consistent finding in all 22 patients investigated in this study. Table 2 shows the mean apolipoprotein concentrations of all patients on admission and at defined time intervals post infarction. The data has been subdivided into those patients who were receiving TPA (TPA patients), and those not receiving the drug (non-TPA patients). The number of patients from whom blood samples were collected differs at each time interval because during the post-infarction period 14 patients (12 non-TPA and 2 TPA) died, whilst the remainder were discharged at varying times.
Apolipoprotein response
During the first 7 days following infarction, marked changes in apolipoprotein concentrations (and also their ratios) were evident. Apo A-I levels steadily declined to a mean minimum value after 7 days that was 25% lower than the mean on admission. At 12h post-infarction Apo B concentrations had increased, but then steadily declined, the mean value reaching a nadir of 16% below the admission mean by 72 h.
From 7 days post-infarction onwards, both Apo A-I and Apo B concentrations slowly increased without evidence of major fluctuations. However, even 20 days after admission, apolipoprotein concentrations had not yet returned to their admission levels. The overall pattern of apolipoprotein response following infarction observed in this study is consistent with that reported by other workers.":"
Between individual patients, almost twice as much variation occurred at each time interval in the levels of Apo B compared to Apo A-I, as evidenced by a larger standard deviation. This individual variability was sufficient to prevent the observed patterns from being categorised as a predictable or acute phase response.
During the first week following infarction, no significant difference in the pattern of apolipoprotein response was observed between those patients receiving TPA and those not receiving this drug (Table I) . As only limited data is available on the TPA group after one week, an objective comparison between the groups cannot be made past this time. However, it is clear that during the period of major perturbation to apolipoprotein levels (the first week following infarction), the administration of thrombolytic agents does not cause an alteration in the pattern of response.
To highlight the similarity between these patient subgroups, Fig. I shows the pattern of response of two individual patients, one receiving TPA (case study I), the other not receiving TPA (case study 2). In the latter case, the patient did not actually suffer a myocardial infarction until 7 days after admission (it is noteworthy that the pre-infarct apolipoprotein values are not significantly different to the first post-infarct values). In both patients, the concentrations of both Apo A-I and Apo B initially declined postinfarction, with Apo B falling earlier than Apo A-I. Following these decreases, the levels of both apolipoproteins rose steadily. Also, in each patient, a double 'crossover' in apolipoprotein concentration was observed.
CONCLUSION
The patterns of response observed in our study suggest that apolipoproteins A-I and B do not behave as acute phase proteins following the trauma of myocardial infarction. The wide fluctuations in apolipoprotein concentrations observed during the first week had ceased in all cases by day 14. We therefore recommend that assessment of a patient's apolipoprotein status should not be undertaken until at least two weeks after infarction.
